Display options
Cite
Giedl J, Rogler A, Wild A, et al. TERT Core Promotor Mutations in Early-Onset Bladder Cancer. J Cancer. 2016;7(8):915-20doi: 10.7150/jca.15006.
Giedl, J., Rogler, A., Wild, A., Riener, M. O., Filbeck, T., Burger, M., Rümmele, P., Hurst, C., Knowles, M., Hartmann, A., Zinnall, U., & Stoehr, R. (2016). TERT Core Promotor Mutations in Early-Onset Bladder Cancer. Journal of Cancer, 7(8), 915-20. https://doi.org/10.7150/jca.15006
Giedl, Johannes, et al. "TERT Core Promotor Mutations in Early-Onset Bladder Cancer." Journal of Cancer vol. 7,8 (2016): 915-20. doi: https://doi.org/10.7150/jca.15006
Giedl J, Rogler A, Wild A, Riener MO, Filbeck T, Burger M, Rümmele P, Hurst C, Knowles M, Hartmann A, Zinnall U, Stoehr R. TERT Core Promotor Mutations in Early-Onset Bladder Cancer. J Cancer. 2016 May 07;7(8):915-20. doi: 10.7150/jca.15006. eCollection 2016. PMID: 27313781; PMCID: PMC4910583.
Copy Download .nbib Format: NLM
Share it on

J Cancer. 2016 May 07;7(8):915-20. doi: 10.7150/jca.15006. eCollection 2016.

TERT Core Promotor Mutations in Early-Onset Bladder Cancer.

Journal of Cancer

Johannes Giedl, Anja Rogler, Andreas Wild, Marc-Oliver Riener, Thomas Filbeck, Maximilian Burger, Petra Rümmele, Carolyn Hurst, Margaret Knowles, Arndt Hartmann, Ulrike Zinnall, Robert Stoehr

Affiliations

  1. 1. Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany;
  2. 2. Department of Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany;
  3. 3. Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany;
  4. 4. Section of Experimental Oncology, Leeds Institute of Cancer and Pathology, University of Leeds, St. James's University Hospital, Leeds, United Kingdom;
  5. 1. Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany;; 5. Institute of Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.

PMID: 27313781 PMCID: PMC4910583 DOI: 10.7150/jca.15006

Abstract

Activating mutations in the core promoter of the TERT gene have been described in many different tumor entities. In vitro models showed a two- to fourfold increase in transcriptional activity of the TERT promoter through creation of a consensus binding motif for Ets/TCF transcription factors caused by these mutations. TERT core promoter mutations are the most common mutations in bladder cancer with a frequency between 55.6% and 82.8% described so far, and are independent of stage and grade. Since limited data on molecular alterations of early-onset bladder tumors exists, we assessed the frequency of TERT core promoter mutations in early-onset bladder cancer. Two cohorts of bladder tumors (early-onset patient group; n=144 (age of onset of disease ≤45 years); unselected, consecutive group; n=125) were examined for TERT core promoter mutations. After microdissection and extraction of DNA the corresponding hotspot regions in the TERT core promoter were examined by Sanger-sequencing or a SNaPshot approach. A significantly lower frequency of TERT core promoter mutations was found in tumors from the early-onset cohort compared to the consecutive cohort (57.6% vs. 84.8%, p<0.001). Among the early-onset cohort cases younger than the cohort's median age of 39 years at disease onset showed a significantly reduced number of TERT promoter mutations (31/67, 46,3%) than cases aged between 39 and 45 years (52/77, 67.5%; p=0.012). This association was not found in the consecutive cases. Mutation status was independent of tumor stage and grade. We conclude that in tumors from early-onset bladder cancer patients TERT core promoter mutations are not as frequent as in bladder tumors from consecutive cases, but seem to play an important role there as well. In patients below 39 years of age TERT core promoter mutations are a more infrequent event, suggesting different mechanisms of tumorigenesis in these young patients.

Keywords: TERT; bladder cancer; early-onset; mutation; sequencing.

References

  1. Oncogene. 2014 Oct 16;33(42):4978-84 - PubMed
  2. Virchows Arch. 2014 Aug;465(2):119-33 - PubMed
  3. Virchows Arch. 2015 May;466(5):589-94 - PubMed
  4. Cancer Res. 2013 Dec 15;73(24):7162-7 - PubMed
  5. J Pathol. 2007 Jan;211(1):18-25 - PubMed
  6. Oncotarget. 2014 Dec 15;5(23):12428-39 - PubMed
  7. Trends Biochem Sci. 2013 Sep;38(9):426-34 - PubMed
  8. Adv Anat Pathol. 2011 Jan;18(1):79-89 - PubMed
  9. Eur Urol. 2014 Feb;65(2):367-9 - PubMed
  10. Pathol Oncol Res. 2016 Jan;22(1):67-70 - PubMed
  11. J Urol. 2010 Aug;184(2):459-63 - PubMed
  12. Int J Cancer. 2015 Oct 1;137(7):1621-9 - PubMed
  13. Eur Urol. 2014 Feb;65(2):360-6 - PubMed
  14. Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6 - PubMed
  15. Science. 2013 Feb 22;339(6122):959-61 - PubMed
  16. Pathobiology. 2015;82(2):53-7 - PubMed
  17. Mod Pathol. 2014 Nov;27(11):1540-8 - PubMed
  18. Eur Urol. 2005 Jan;47(1):58-63 - PubMed
  19. Histopathology. 2016 Jul;69(1):107-13 - PubMed
  20. Science. 2015 Feb 27;347(6225):1006-10 - PubMed
  21. J Hematol Oncol. 2014 Jul 20;7:47 - PubMed
  22. Eur Urol. 2014 Feb;65(2):274-7 - PubMed

Publication Types